Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 11/20 | 0.78 |
| ▸ | EGFR | P00533 | 5/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 4/20 | 0.48 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654156 | 0.88 | SYK (1.00) | SYKEGFRJAK3AURKABTK | |
| SCHEMBL17915975 | 0.85 | SYK (0.84) | SYKEGFRJAK3AURKABTK | |
| SCHEMBL12321383 | 0.85 | SYK (0.55) | SYKEGFRJAK3BTKITK | |
| SCHEMBL301484 | 0.84 | EGFR (0.57) | SYKEGFRJAK3AURKABTK | |
| SCHEMBL301856 | 0.83 | EGFR (0.64) | SYKEGFRJAK3STAT6BTK | |
| SCHEMBL305410 | 0.82 | SYK (0.59) | SYKEGFRJAK3AURKAITK | |
| SCHEMBL12111163 | 0.82 | BRD4 (0.59) | SYKEGFRJAK3BTKITK | |
| SCHEMBL300797 | 0.82 | SYK (0.53) | SYKEGFRJAK3AURKABTK | |
| SCHEMBL301348 | 0.82 | EGFR (0.55) | SYKEGFRJAK3AURKABTK | |
| SCHEMBL270179 | 0.82 | SYK (0.78) | SYKEGFRJAK3AURKABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2010017122-A2 | METHODS OF TREATING THALASSEMIA | TARGEGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | SYK 59/4885EGFR 335/4885JAK3 4/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SYK 281/4885EGFR 181/4885JAK3 3/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | SYK 281/4885EGFR 181/4885JAK3 3/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | SYK 281/4885EGFR 181/4885JAK3 3/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | SYK 43/4885EGFR 4628/4885JAK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.